Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor is a phase 1/2, interventional study registered as NCT07433283 by Sichuan Enray Pharmaceutical Sciences Company, with a registry enrolment figure of 54 participants, started 2024-11-12 and due to reach its primary completion in 2026-12-31. Interventions recorded: Carbon Nanoparticle-Loaded Iron [CNSI-Fe]; Carbon Nanoparticle-Loaded Iron. Conditions listed: Tumor, Solid; Lung Cancer; Pancreas Cancer; Thyroid Cancer; Colorectal Cancer; Cervical Cancer; Vulva Cancer. Primary outcome: Incidence and severity of participants with treatment-related adverse events as assessed by CTCAE v5.0. Pancreatic eligibility wording from the registry: "Stage Ib: patients with advanced solid tumors confirmed by histology or cytology, and the current standard therapy is ineffective (disease progression after treatment or treatment is not tolerated) or there is no effective standard treatment, such as soft tissue sarcoma, refractory thyroid cancer, c". Sites: China. No results are recorded here; the registry entry is the source.